In particular, combining DZNeP with venetoclax was shown to significantly eliminate CD117+ (c-KIT) AML blasts, hence indicating substantial effects on tumor stem cells (Momparler et al., 2012). The gene discussed is KIT; the disease is acute myeloid leukemia.